<DOC>
	<DOC>NCT00004810</DOC>
	<brief_summary>OBJECTIVES: I. Assess the safety and efficacy of 4-aminosalicylic acid in patients with mildly to moderately severe ulcerative colitis.</brief_summary>
	<brief_title>Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by extent of disease. Patients are randomly assigned to oral 4-aminosalicylic acid (4-ASA) or placebo administered daily for 6 weeks. Optional 4-ASA is available to all patients for up to 1 year. Concurrent therapy with low-dose sulfasalazine, prednisone, or equivalent is allowed.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Aminosalicylic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Mildly to moderately severe ulcerative colitis Patient age: 18 to 80</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>gastrointestinal disorders</keyword>
	<keyword>rare disease</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>